{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"4.1","value":"3.1"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"5.7","value":"1.6"},{"groupId":"OG002","lowerLimit":"2.9","upperLimit":"4.3","value":"3.0"},{"groupId":"OG003","lowerLimit":"2.9","upperLimit":"5.6","value":"3.3"},{"groupId":"OG004","lowerLimit":"2.8","upperLimit":"5.0","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"31"}],"units":"Participants"}],"description":"Time to MCyR is defined as the time from first dose of dasatinib until the first day MCyR criteria are met, computed only for participants whose best response is MCyR. (Based on \\>=20 Metaphases)","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"MEDIAN","populationDescription":"All treated participants with MCyR","reportingStatus":"POSTED","timeFrame":"From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months)","title":"Time to Major Cytogenetic Response (MCyR)","type":"SECONDARY","unitOfMeasure":"months"}